Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Period	Debt/Equity
2016-12-31	0.07
2017-12-31	0.36
2018-12-31	0.24
2019-12-31	0.94
2020-12-31	0.16
2021-12-31	0.16
2022-12-31	0.15
2023-12-31	0.06
2024-12-31	0.10

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PTGX	$103.10	-0.63%	0.32M
3
4
5

Protagonist Therapeutics Inc. (PTGX) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Protagonist Therapeutics Inc. Data in Excel

More PTGX Financial Data